Bladder Cancer
NMIBC, MIBC, and metastatic bladder cancer
DefinitionClick to collapse
Bladder cancer is a malignant neoplasm arising from the urothelium, the specialized transitional epithelium lining the urinary bladder, renal pelvis, ureters, and proximal two-thirds of the urethra. Urothelial (transitional cell) carcinoma is the most common histology in the United States and Europe [MS-7]. Approximately 75% of newly diagnosed cases present as non–muscle-invasive disease (Ta, T1, CIS), while the remainder are muscle-invasive (≥T2) or metastatic [MS-4]. The bladder is a hollow, muscular organ located in the pelvis, with the urothelium serving as the first line of defense against urine-borne toxins. Embryologically, the urothelium derives from the urogenital sinus and mesonephric duct contributions. The AJCC TNM staging system (8th edition) defines depth of invasion (T category), nodal involvement (N), and distant metastasis (M) [ST-1]. Clinical staging combines bimanual examination under anesthesia, endoscopic resection, and imaging, while pathologic staging requires cystectomy with lymph node dissection [BL-1]. The natural history ranges from indolent low-grade papillary tumors to aggressive high-grade carcinomas with metastatic potential.
EpidemiologyClick to collapse
The American Cancer Society estimates 84,530 new cases of urinary bladder cancer (64,730 males and 19,800 females) and 17,870 deaths (12,640 males and 5,230 females) in the United States in 2026 [1]. Bladder cancer is the sixth most common cancer in the US, with a median age at diagnosis of 73 years; it is rarely diagnosed in individuals under age 40 [2]. Age-adjusted incidence is approximately 3–4 times higher in males than females, and White individuals have a significantly higher incidence than Black individuals [1,3]. Globally, bladder cancer incidence and mortality vary widely, with the highest rates in Southern and Western Europe, Northern America, and Northern Africa, partly due to Schistosoma haematobium infection in endemic areas [5]. In the US, mortality rates have been declining over the past few decades, but racial disparities persist, with Black patients having lower incidence but higher mortality [5]. The clinical spectrum is divided into non–muscle-invasive bladder cancer (NMIBC; ~75% of new cases), muscle-invasive bladder cancer (MIBC; ~20–25%), and metastatic disease (~5% at initial presentation) [2,20]. Five-year relative survival ranges from 96% for NMIBC (in situ) to 69% for localized disease, 38% for regional disease, and 6% for distant metastatic disease [2].
SubtypesClick to collapse
Conventional urothelial carcinoma (infiltrating)
The most common type of invasive bladder cancer, composed of tumor cells with urothelial differentiation. Includes variants with squamous differentiation, glandular differentiation, or trophoblastic differentiation.
Noninvasive papillary urothelial carcinoma (low-grade and high-grade)
Papillary neoplasms confined to the mucosa (Ta). Low-grade have minimal cytologic atypia; high-grade show marked atypia and architectural disarray.
Urothelial carcinoma in situ (CIS)
High-grade noninvasive flat lesion confined to the mucosa. Often multifocal and associated with invasive disease.
Micropapillary urothelial carcinoma
Aggressive subtype characterized by small papillary clusters of tumor cells in lacunar spaces, mimicking serous carcinoma.
Plasmacytoid urothelial carcinoma
Subtype with discobesive cells with plasmacytoid morphology, often with signet-ring features.
Sarcomatoid urothelial carcinoma
Biphasic tumor with both carcinomatous and sarcomatoid (mesenchymal) components.
Small cell / neuroendocrine carcinoma
High-grade neuroendocrine carcinoma similar to small cell lung cancer. Can be pure or mixed with urothelial carcinoma.
Squamous cell carcinoma (pure)
Exclusively squamous differentiation with keratinization and/or intercellular bridges. Must exclude mixed histology.
Adenocarcinoma (including urachal carcinoma)
Pure glandular neoplasm. Urachal carcinoma arises in the urachal remnant at bladder dome.
Primary bladder sarcoma
Mesenchymal tumors including rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, etc.
Other rare subtypes
Includes nested, tubular/microcystic, lymphoepithelioma-like, giant cell, lipid-rich, clear cell, poorly differentiated, and others.
Molecular PathogenesisClick to collapse
Bladder cancer is characterized by a high mutational burden, ranking third among all cancers per The Cancer Genome Atlas [251,252]. Comprehensive genomic profiling of advanced urothelial carcinoma revealed a mean of 2.6 clinically relevant genetic alterations per case, with the most frequent being CDKN2A (34%), FGFR3 (21%), PIK3CA (20%), and ERBB2 (17%) [253]. FGFR3 alterations (including sequence variants, copy number variants, and rearrangements) are particularly common in low-grade Ta tumors and define a subset responsive to erdafitinib therapy [291,295]. TP53 mutations are hallmark of high-grade, muscle-invasive disease and are associated with genomic instability. The panel recommends evaluation of microsatellite instability (MSI) and mismatch repair (MMR) status for metastatic disease, as MSI-H tumors may benefit from immunotherapy [BL-I 3 of 3]. HER2 overexpression (IHC 3+ or 2+) is found in approximately 20% of advanced bladder cancers, enabling treatment with fam-trastuzumab deruxtecan-nxki [34,303]. Molecular classification into luminal, basal, and other subtypes is being explored but not yet routine. Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker after cystectomy, with FDA-approved tumor-informed multiplex PCR-NGS assays recommended for risk stratification and to determine use of adjuvant immunotherapy [BL-I 2 of 3]. In NMIBC, biomarkers are currently limited to research settings [BL-I 2 of 3]. Germline testing is recommended for patients with younger age or Lynch syndrome-related personal/family history, as Lynch syndrome (especially MSH2 mutations) strongly predisposes to upper tract and bladder urothelial carcinoma [7,11].
Risk FactorsClick to collapse
Cigarette smoking
Strongest known risk factor; accounts for approximately 50% of cases in men and 30% in women. Former smokers remain at elevated risk, though the risk decreases with cessation [10].
Occupational exposures
Aromatic amines (e.g., benzidine, beta-naphthylamine) used in dye, rubber, leather, and printing industries; also polycyclic aromatic hydrocarbons [6].
Pelvic radiation therapy
Prior radiation for prostate, cervical, or other pelvic cancers increases risk of bladder cancer, especially high-grade tumors [3].
Certain medications
Cyclophosphamide (alkylating agent) increases risk; pioglitazone use for diabetes has been associated with increased risk [3].
Chronic infection or irritation
Chronic urinary tract infections, long-term indwelling catheters, and Schistosoma haematobium infection (especially for squamous cell carcinoma) [3,5].
Male sex
Incidence is 3–4 times higher in males than females, though females present with more advanced stage [1].
White race
Incidence is approximately 2 times higher in White individuals than in Black individuals in the US, though Black individuals have higher mortality [1,3].
Family history and genetic syndromes
Personal or family history of bladder cancer increases risk; Lynch syndrome (especially MSH2 mutations) strongly predisposes to urothelial carcinoma [7,11].
Obesity and diabetes
Obesity (BMI >30) and type 2 diabetes are associated with modestly increased risk; diabetes may act through insulin resistance and hyperinsulinemia [4].
Low fluid intake
High fluid intake may be protective; low intake may concentrate carcinogens in urine; not quantified in the source as a primary risk factor but suggested.
Clinical FeaturesClick to collapse
Typical Presentation
Bladder cancer most commonly presents with microscopic or gross hematuria, which is the classic alarm symptom. Approximately 75% of newly detected cases are non–muscle-invasive disease (Ta, T1, CIS) [20]. Other frequent presentations include urinary frequency, urgency, or dysuria due to bladder irritation or reduced capacity. Less commonly, patients may present with a urinary tract infection or, in advanced disease, upper tract obstruction or flank pain. The median age at diagnosis is 73 years, and the disease is rare in individuals <40 years [1,2]. Risk factors include smoking, male sex, white race, occupational exposures, and Lynch syndrome [3-7]. A substantial hereditary component is recognized, particularly with Lynch syndrome [7,11]. Initial evaluation includes office cystoscopy, urine cytology, and imaging of the upper tract before TURBT [BL-1].
Symptoms
Hematuria
Microscopic or gross hematuria; most common presenting symptom.
Urinary frequency/urgency
Irritative voiding symptoms secondary to tumor-associated inflammation or reduced bladder capacity.
Urinary tract infection
May be the presenting complaint, especially if irritative symptoms are present.
Upper tract obstruction/pain
Flank pain or hydronephrosis from ureteral involvement in advanced disease.
Signs
Cystoscopic lesion
Visible papillary or sessile tumor on office cystoscopy.
Palpable mass on EUA
Bimanual examination under anesthesia may reveal a palpable mass if muscle-invasive or extravesical disease.
Positive urine cytology
Exfoliated malignant urothelial cells in urine.
Red FlagsClick to collapse
Gross hematuria (visible blood in urine) – requires immediate urologic evaluation.
Persistent microscopic hematuria in patients with risk factors (age >40, smoking, occupational exposures).
Urinary frequency, urgency, or dysuria without infection or refractory to treatment.
Flank pain or hydronephrosis suggesting ureteral obstruction.
Palpable mass on bimanual examination under anesthesia.
Positive urine cytology even with normal cystoscopy – may indicate CIS or upper tract tumor.
Family history of Lynch syndrome or personal history of Lynch-related cancers.
Age <40 with hematuria – consider germline testing.
Sessile or high-grade tumor on cystoscopy – high risk of muscle invasion.
Rapid recurrence after initial TURBT or intravesical therapy.
InvestigationsClick to collapse
Diagnostic
Cystoscopy (office)
Direct visualization of bladder lesions; can be enhanced with blue light or narrow-band imaging.
Transurethral resection of bladder tumor (TURBT)
Histologic diagnosis and initial staging; must include muscularis propria for accurate staging.
Urine cytology
Detection of malignant urothelial cells; high specificity.
Enhanced cystoscopy (blue light, narrow-band imaging)
Improved detection of flat lesions (CIS) and small tumors.
Examination under anesthesia (EUA)
Bimanual assessment of tumor fixity and local extent.
Staging
CT urography (CTU)
Preferred imaging for upper tract evaluation and local staging.
MR urography (MRU)
Alternative when CTU is contraindicated (poor renal function, contrast allergy).
Chest CT (preferred) or chest x-ray
Detection of pulmonary metastases.
Bone scan or MRI of spine/pelvis
Detection of bone metastases.
FDG-PET/CT (category 2B)
May alter management in high-risk MIBC.
Abdomen/pelvis CT or MRI with IV contrast
Local and regional staging.
CBC, chemistry profile (including alkaline phosphatase)
Baseline assessment; alkaline phosphatase may be elevated with bone metastases.
Glomerular filtration rate (GFR)
Assess eligibility for cisplatin-based chemotherapy.
Biomarkers
FGFR3 genomic alterations (including sequence variants, copy number variants, rearrangements/fusions)
Identify patients eligible for erdafitinib (FGFR inhibitor).
HER2 immunohistochemistry (IHC)
Identify patients eligible for fam-trastuzumab deruxtecan-nxki.
Microsatellite instability (MSI) and/or mismatch repair (MMR) status
Identify patients eligible for checkpoint inhibitor therapy.
Circulating tumor DNA (ctDNA) for minimal residual disease (MRD)
Prognostic and predictive for adjuvant immunotherapy after cystectomy.
Germline multigene panel testing (MGPT)
Identify Lynch syndrome and other hereditary cancer syndromes.
StagingClick to collapse
AJCC 8th edition, 2017 [19]
T Categories
| Stage | Description |
|---|---|
| TX | Primary tumor cannot be assessed. |
| T0 | No evidence of primary tumor. |
| Ta | Noninvasive papillary carcinoma. |
| CIS (Tis) | Urothelial carcinoma in situ: 'flat tumor'. |
| T1 | Tumor invades lamina propria (subepithelial connective tissue). |
| T2a | Tumor invades superficial muscularis propria (inner half). |
| T2b | Tumor invades deep muscularis propria (outer half). |
| T3a | Tumor invades perivesical tissue microscopically. |
| T3b | Tumor invades perivesical tissue macroscopically (extravesical mass). |
| T4a | Extravesical tumor invades prostatic stroma, seminal vesicles, uterus, vagina. |
| T4b | Extravesical tumor invades pelvic wall, abdominal wall. |
N Categories
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed. |
| N0 | No regional lymph node metastasis. |
| N1 | Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). |
| N2 | Multiple regional lymph node metastases in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph nodes). |
| N3 | Lymph node metastasis to the common iliac lymph nodes. |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastasis. |
| M1a | Distant metastasis limited to lymph nodes beyond the common iliacs. |
| M1b | Non-lymph-node distant metastases. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage 0a | Ta, N0, M0 | Noninvasive papillary carcinoma, no nodal or distant spread. | Not specified in guideline | Curative – TURBT ± intravesical therapy. |
| Stage 0is | CIS (Tis), N0, M0 | Flat carcinoma in situ, high risk of progression if untreated. | Not specified in guideline | Curative – TURBT ± intravesical BCG. |
| Stage I | T1, N0, M0 | Tumor invades lamina propria, no nodal or distant spread. | Not specified in guideline | Curative – TURBT ± intravesical therapy; repeat TURBT for high-risk. |
| Stage II | T2a or T2b, N0, M0 | Muscle-invasive disease confined to bladder. | Not specified in guideline | Curative – neoadjuvant cisplatin-based chemotherapy + cystectomy or bladder preservation with chemoradiation. |
| Stage IIIA | T3a, N0, M0; T3b, N0, M0; T4a, N0, M0; T1–T4a, N1, M0 | Extravesical tumor extension or single regional lymph node metastasis. | Not specified in guideline | Potentially curative – neoadjuvant chemotherapy + cystectomy or chemoradiation; in N1, may need systemic therapy first. |
| Stage IIIB | T1–T4a, N2–N3, M0 | Multiple regional lymph node metastases or common iliac node involvement. | Not specified in guideline | Potentially curative – induction systemic therapy or chemoradiation; subsequent consolidation if response. |
| Stage IVA | T4b, Any N, M0; Any T, Any N, M1a | Tumor invades pelvic/abdominal wall or distant nodes beyond common iliacs. | Not specified in guideline | Palliative or potentially curative in select responders – systemic therapy ± consolidative local therapy. |
| Stage IVB | Any T, Any N, M1b | Distant organ metastases. | Not specified in guideline | Palliative – systemic therapy; metastasectomy in highly selected oligometastatic patients. |
Staging Pearls
- Clinical staging (c) uses bimanual EUA, TURBT, and imaging; pathologic staging (p) uses cystectomy and lymph node dissection [BL-1].
- Depth of invasion is the most important determinant of prognosis and treatment for localized bladder cancer.
- Muscularis propria must be present in the TURBT specimen for accurate staging; absence may lead to understaging (49% understaged without muscle vs 14% with muscle) [119,120].
- pT1 substaging (microscopic/focal vs extensive invasion) may have prognostic value but is not yet widely standardized [21-23].
- The 8th AJCC edition subdivides stage III into IIIA and IIIB, and stage IV into IVA and IVB [19].
- Positive urine cytology with negative cystoscopy requires evaluation of upper tracts and prostatic urethra to identify occult disease [BL-5].
- Understaging is common: 42% of patients are upstaged after cystectomy [155].
- Histologic grade is reported as low-grade or high-grade for urothelial carcinomas; for squamous/adenocarcinoma, G1–G3 is used [ST-1].
SurveillanceClick to collapse
Clinical Follow Up Schedule
| Group | Schedule |
|---|---|
| Low-risk NMIBC | Cystoscopy at 3 and 12 months, then annually up to 5 years; after 5 years as clinically indicated [BL-E 1 of 6] |
| Intermediate-risk NMIBC | Cystoscopy at 3, 6, 12 months; then every 6 months through year 5, then annually as clinically indicated. Urine cytology at 3, 6, 12 months, then every 6 months, then annually [BL-E 2 of 6] |
| High-risk NMIBC | Cystoscopy every 3 months for year 1, every 6 months for years 2-5, then annually. Urine cytology every 3 months for year 1, every 6 months for years 2-5, then annually [BL-E 2 of 6] |
| Post-cystectomy NMIBC/MIBC | CTU/MRU at 3 and 12 months, then annually for up to 5 years; then renal US annually. Chest CT every 3-6 months for MIBC for first 2 years, then annually. Consider urine cytology/urethral wash every 6-12 months [BL-E 3,4 of 6] |
| Post-bladder sparing (partial cystectomy or chemoradiation) | Cystoscopy every 3 months for year 1, every 6 months for years 2-5, then annually. Imaging: CTU/MRU and chest CT every 3-6 months for MIBC for first 2 years, then annually [BL-E 5 of 6] |
| Metastatic disease surveillance | CT chest/abdomen/pelvis every 3-6 months if clinically indicated or with new symptoms. CBC/CMP every 1-3 months. B12 annually post-cystectomy [BL-E 6 of 6] |
Imaging Strategy
- NMIBC: Upper tract imaging (CTU or MRU) at baseline for all; for high-risk NMIBC, repeat at 12 months and every 1-2 years up to 10 years [BL-A 1 of 5]
- MIBC: CTU/MRU (or MRU if contrast contraindicated) for staging and follow-up. Chest CT preferred over x-ray. FDG-PET/CT (category 2B) may be used for high-risk or suspected metastasis [BL-A 2,3 of 5]
- Post-cystectomy: CTU/MRU at 3 and 12 months, then annually; chest CT every 3-6 months for first 2 years [BL-E 3,4 of 6]
- Metastatic: CT chest/abdomen/pelvis every 3-6 months; FDG-PET/CT may be used [BL-E 6 of 6]
- Bone imaging: only for clinical suspicion or symptoms (MRI, FDG-PET/CT, or bone scan) [BL-A 3 of 5]
- Brain MRI: only for symptomatic or high-risk patients (e.g., small cell histology) [BL-A 3 of 5]
Laboratory Monitoring
- Renal function (electrolytes, creatinine) every 3-6 months for first 2 years, then annually (post-cystectomy or on active therapy)
- Liver function (AST, ALT, bilirubin, alkaline phosphatase) every 3-6 months for first 2 years, then annually
- CBC and comprehensive metabolic panel (CMP) every 3-6 months if received chemotherapy
- Vitamin B12 annually after cystectomy (especially with continent diversion) [BL-E 3,4,6 of 6]
- Urine cytology: for intermediate/high-risk NMIBC at scheduled intervals; for post-cystectomy, consider every 6-12 months including urethral wash if high-risk features (positive urethral margin, multifocal CIS, prostatic urethral invasion) [BL-E 2,3,4 of 6]
Supportive Follow Up
- Smoking cessation counseling and treatment (NCCN Guidelines for Smoking Cessation) [BL-1]
- Distress screening using NCCN Distress Thermometer [b]
- Genetic counseling referral if younger age or Lynch syndrome family history [BL-1]
- Survivorship care per NCCN Guidelines for Survivorship (e.g., late effects, health promotion) [BL-E 1-6 of 6]
- Palliative care referral for advanced disease (NCCN Guidelines for Palliative Care)
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Hematuria (microscopic or gross) | Evaluation with cystoscopy, imaging; TURBT for visible lesions. |
| Urinary frequency/urgency, reduced bladder capacity | Symptom management; treat underlying tumor. |
| Upper tract obstruction/pain (advanced disease) | Stenting, percutaneous nephrostomy, systemic therapy, palliative RT. |
| Metastatic spread (lymph nodes, bone, liver, lung, CNS) | Systemic therapy, palliative RT, metastasectomy in select cases. |
Supportive CareClick to collapse
The NCCN Guidelines emphasize a multidisciplinary approach to supportive care, including screening for distress, social determinants of health, and smoking cessation [b, NCCN Guidelines for Distress Management]. Referral to the NCCN Guidelines for Survivorship, Palliative Care, and Management of Immune Checkpoint Inhibitor-Related Toxicities is recommended. No single supportive care plan fits all patients; individualization based on disease stage, treatment modality, and patient preference is essential.
Not specifically detailed; NCCN Guidelines for Survivorship and Palliative Care include general recommendations for cancer-related malnutrition and cachexia. For patients undergoing cystectomy or chemoradiation, nutritional assessment and support (dietary counseling, oral supplements, or enteral/parenteral nutrition) may be indicated.
Not explicitly provided; antiemetic prophylaxis should follow standard guidelines for emetogenic chemotherapy (e.g., cisplatin-based regimens require high-dose corticosteroids + NK1 antagonist + 5-HT3 antagonist). The guideline references growth factor support for ddMVAC but not specific antiemetics.
Growth factor support (G-CSF) is recommended for patients receiving ddMVAC (dose-dense MVAC) in both neoadjuvant and metastatic settings [171,197]. It is also recommended for other myelosuppressive regimens as clinically indicated, but no specific dosing schedule is provided.
Not addressed in the bladder cancer-specific algorithm; general oncology VTE prophylaxis per NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease should be followed, particularly in patients undergoing major surgery or receiving chemotherapy.
Refer to NCCN Guidelines for Palliative Care. Pain management for bone metastases includes palliative RT (30 Gy/10 fractions or 21 Gy/3 fractions) [BL-H 1 of 3]. For pelvic recurrence, consider palliative TURBT or RT.
Screening for distress using the NCCN Distress Thermometer and Problem List is recommended at initial evaluation [b]. Referral to psychosocial services, genetic counseling (if indicated), and patient advocacy resources (e.g., Bladder Cancer Advocacy Network) may be beneficial. The NCCN Guidelines for Distress Management provide further guidance.
Not specifically mentioned. Patients receiving chemotherapy (especially cisplatin) should have dental evaluation and management of oral mucositis as per standard oncology supportive care guidelines. DPYD testing is recommended before fluoropyrimidine therapy [BL-G 6 of 8].
PrognosisClick to collapse
Bladder cancer is the sixth most common cancer in the United States, with an estimated 84,530 new cases and 17,870 deaths expected in 2026 [1]. The median age at diagnosis is 73 years [2]. The clinical spectrum is divided into non–muscle-invasive (NMIBC), muscle-invasive (MIBC), and metastatic disease, each with distinct prognosis and management. For NMIBC, 31% to 78% of patients experience recurrence within 5 years depending on initial stage, grade, size, and multiplicity [24]. Untreated carcinoma in situ (CIS) progresses to muscle-invasive disease in 50% of patients within 5 years; even with treatment, 30% to 40% progress within 10 years [125]. For MIBC, neoadjuvant cisplatin-based chemotherapy plus radical cystectomy improves median survival from 46 to 77 months compared to cystectomy alone [163]. Bladder-preserving trimodality therapy yields 5-year overall survival (OS) rates of approximately 49% to 73% in selected patients [220,227,228]. In the metastatic setting, first-line enfortumab vedotin plus pembrolizumab improved median OS to 31.5 months versus 16.1 months with platinum-based chemotherapy (HR 0.47; 95% CI 0.38–0.58) [260]. Avelumab maintenance therapy after first-line platinum-based chemotherapy provides a median OS of 21.4 months versus 14.3 months with best supportive care (HR 0.69; 95% CI 0.56–0.86) [282].
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| NMIBC – Low risk | Not explicitly stated; recurrence rate 31-78% within 5 years [24] | Low-risk includes solitary Ta low-grade ≤3 cm; TURBT alone is often curative. |
| NMIBC – High risk with CIS | 50% progress to MIBC within 5 years if untreated; with treatment, 30-40% progress within 10 years [125] | High-risk includes T1 high-grade, CIS, multifocal, large tumors; BCG induction + maintenance is recommended. |
| MIBC – Stage II (cT2 N0) | Neoadjuvant chemotherapy + cystectomy: median OS 77 months vs 46 months with cystectomy alone [163] | 5-year OS not provided; median survival reported. |
| MIBC – Bladder preservation (trimodality) | Approximately 49% (RTOG 89-03) to 73% (RTOG 0233) [220,228] | Candidates: solitary tumors, no hydronephrosis, no extensive CIS. |
| Metastatic – First-line | Not stated; median OS 31.5 months with EV+Pembro, 16.1 months with chemo [260] | Enfortumab vedotin + pembrolizumab is preferred first-line category 1. |
| Metastatic – Post-platinum maintenance | Median OS 21.4 months with avelumab maintenance vs 14.3 months BSC [282] | Avelumab maintenance for patients without progression after platinum-based chemo. |
Prognostic Factors
- NMIBC: tumor grade, stage (Ta vs T1), size, multiplicity, recurrence rate, presence of CIS, lymphovascular invasion, prostatic urethral invasion, histologic subtypes (micropapillary, plasmacytoid, sarcomatoid, small cell) [113,126]
- MIBC: depth of invasion (T2 vs T3 vs T4), nodal status, lymphovascular invasion, margin status, response to neoadjuvant chemotherapy, histologic subtypes, molecular biomarkers (ctDNA, FGFR3, HER2)
- Metastatic: performance status, presence of visceral metastases, alkaline phosphatase levels, prior response to platinum therapy
- Biomarkers: ctDNA-MRD positivity post-cystectomy is prognostic; FGFR3 alterations predict response to erdafitinib; HER2 IHC 3+ or 2+ predicts response to fam-trastuzumab deruxtecan
Follow UpClick to collapse
Post Curative Treatment
Follow-up schedules are stratified by disease type and treatment modality. No single plan fits all; duration and frequency should be individualized and may extend beyond 5 years after shared decision-making [BL-A 1 of 5].
Surveillance Rationale
Early detection of recurrence (local, regional, or distant) and late effects of treatment. Recurrence patterns differ by initial stage and treatment. For preserved bladder, cystoscopy and urine cytology are key; for post-cystectomy, imaging of upper tracts and chest is essential. Vitamin B12 monitoring is needed after cystectomy with urinary diversion.
Late Effects Screening
- Vitamin B12 deficiency: annual B12 assessment after cystectomy with urinary diversion (especially continent diversion) [BL-E 3,4 of 6]
- Renal function: electrolyte and creatinine monitoring every 3-6 months for first 2 years, then annually
- Liver function: AST, ALT, bilirubin, alkaline phosphatase every 3-6 months for first 2 years, then annually
- Second primary urothelial tumors: upper tract imaging (CTU or MRU) at baseline and periodically for high-risk NMIBC (every 1-2 years up to 10 years) [BL-A 1 of 5]
- Osteoporosis/ bone health: not specific; bone scan if symptoms
- Cardiovascular: not specific; general cancer survivorship guidelines apply
Recurrence Patterns
NMIBC: most recurrences are non–muscle-invasive and can be treated endoscopically; progression to MIBC occurs in a subset. MIBC post-cystectomy: local recurrence 10-30%, distant metastases more common; upper tract recurrence 0.75-6.4% [238]. Post-bladder preservation: local recurrence in bladder or elsewhere in urothelial tract, plus distant metastases. Metastatic disease: progression on therapy is common; regular imaging every 3-6 months.
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG 8710 (INT-0080) | Neoadjuvant Chemotherapy Plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer | 2003 | 307 | 3 cycles neoadjuvant MVAC followed by radical cystectomy | Radical cystectomy alone | Clinical stage T2-T4a N0 M0 | Overall survival | Median OS 77 months (chemotherapy) vs 46 months (surgery alone); P=0.06; residual disease 15% vs 38% (P<0.001) | 5-year OS not specified; reduction in mortality risk not statistically significant | Established neoadjuvant chemotherapy as standard for MIBC | New England Journal of Medicine |
| BC2001 | Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer | 2012 | 360 | Radiotherapy + concurrent 5-FU + mitomycin C | Radiotherapy alone | Muscle-invasive bladder cancer (T2-T4a N0 M0) | Locoregional disease-free survival | 2-year locoregional DFS 67% vs 54% (HR 0.66; 95% CI 0.49-0.89; P=0.01) | 5-year OS 48% vs 35% (P=0.16); no significant increase in grade 3-4 toxicity | Established chemoradiotherapy as standard for bladder preservation; mitomycin/5-FU preferred radiosensitizer | New England Journal of Medicine |
| Keynote-045 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma | 2017 | 542 | Pembrolizumab 200 mg every 3 weeks | Investigator's choice chemotherapy (paclitaxel, docetaxel, or vinflunine) | Advanced urothelial carcinoma progressing after platinum-based chemotherapy | Overall survival and progression-free survival | Median OS 10.3 vs 7.4 months (HR 0.73; 95% CI 0.59-0.91; P=0.002) | ORR 21.1% vs 11.0%; grade ≥3 AEs 15.0% vs 49.4% | Pembrolizumab became standard second-line therapy (category 1 post-platinum) | New England Journal of Medicine |
| CheckMate 274 | Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma | 2021 | 709 | Adjuvant nivolumab 240 mg every 2 weeks for up to 1 year | Placebo | High-risk muscle-invasive urothelial carcinoma after radical surgery (including UTUC) | Disease-free survival (DFS) in intent-to-treat and PD-L1 ≥1% populations | ITT: median DFS 20.8 vs 10.8 months (HR 0.70; 98.22% CI 0.55-0.90; P<0.001). PD-L1≥1%: HR 0.55 (98.72% CI 0.35-0.85; P<0.001) | Grade ≥3 AEs 17.9% vs 7.2% | Adjuvant nivolumab approved for high-risk MIBC/UTUC post-surgery; category 1 for bladder | New England Journal of Medicine |
| JAVELIN Bladder 100 | Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | 2020 | 700 | Avelumab 10 mg/kg every 2 weeks + best supportive care | Best supportive care alone | Locally advanced or metastatic urothelial carcinoma without progression after first-line platinum-based chemotherapy | Overall survival (ITT and PD-L1+ population) | Median OS 21.4 vs 14.3 months (HR 0.69; 95% CI 0.56-0.86; P=0.001) | OS benefit in all subgroups; grade ≥3 AEs 47.4% vs 25.2% | Avelumab maintenance became standard (category 1) after first-line platinum chemo | New England Journal of Medicine |
| EV-302 (KEYNOTE-A39) | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer | 2024 | 886 | Enfortumab vedotin + pembrolizumab | Gemcitabine + cisplatin or carboplatin | Previously untreated locally advanced or metastatic urothelial carcinoma | Progression-free survival and overall survival | Median PFS 12.5 vs 6.3 months (HR 0.45; 95% CI 0.38-0.54; P<0.001). Median OS 31.5 vs 16.1 months (HR 0.47; 95% CI 0.38-0.58; P<0.001) | ORR 67.7% vs 44.4%; complete response 29.1% vs 12.5%; grade ≥3 AEs 55.9% vs 69.5% | Enfortumab vedotin + pembrolizumab became preferred first-line therapy (category 1) for advanced urothelial carcinoma | New England Journal of Medicine |
| CheckMate 901 | Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma | 2023 | 608 | Nivolumab + gemcitabine-cisplatin (6 cycles) followed by nivolumab maintenance | Gemcitabine-cisplatin alone | Previously untreated unresectable or metastatic urothelial carcinoma | Overall survival and progression-free survival | Median OS 21.7 vs 18.9 months (HR 0.78; 95% CI 0.63-0.96; P=0.02). PFS at 12 months 34.2% vs 21.8% | ORR 57.6% vs 43.1%; complete response 21.7% vs 11.8%; grade ≥3 AEs 61.8% vs 51.7% | Nivolumab + GC is a category 1 first-line option; nivolumab maintenance after chemo | New England Journal of Medicine |
| THOR (Cohort 1) | Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma with FGFR Alterations | 2023 | 266 | Erdafitinib | Docetaxel or vinflunine | Metastatic urothelial carcinoma with susceptible FGFR3/2 alterations after prior treatment including checkpoint inhibitor | Overall survival | Median OS 12.1 vs 7.8 months (HR 0.64; 95% CI 0.47-0.88; P=0.005). Median PFS 5.6 vs 2.7 months (HR 0.58; 95% CI 0.44-0.78; P<0.001) | ORR 45.6% vs 11.5%; grade ≥3 AEs 45.9% vs 46.4% | Erdafitinib is category 1 for FGFR3-mutated advanced urothelial carcinoma post-platinum and post-ICI | New England Journal of Medicine |
| VESPER (GETUG-AFU V05) | Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Muscle-Invasive Bladder Cancer | 2022 | 500 | Neoadjuvant or adjuvant ddMVAC (6 cycles) or GC (4-6 cycles) | ddMVAC vs GC | Nonmetastatic muscle-invasive bladder cancer (cT2-T4a N0 M0) | 3-year progression-free survival | 3-year PFS 66% (ddMVAC) vs 56% (GC) (HR 0.70; 95% CI 0.51-0.96; P=0.025) in neoadjuvant subgroup. Pathologic complete response 42% vs 36% (P=0.21) | Organ-confined response 77% vs 63% (P=0.001); similar grade ≥3 AEs (52% vs 55%) but different toxicity profiles | ddMVAC is preferred neoadjuvant regimen over GC for MIBC | Journal of Clinical Oncology |
| POUT | Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma | 2020 | 261 | Adjuvant gemcitabine + cisplatin or carboplatin (4 cycles) | Surveillance | pT2-pT4 or pN1-3 M0 UTUC after nephroureterectomy | Disease-free survival | 3-year event-free estimates 71% vs 46% (HR 0.45; 95% CI 0.30-0.68; P=0.0001) | Grade ≥3 AEs 44% vs 4% | Adjuvant platinum-based chemotherapy became standard for high-risk UTUC after nephroureterectomy | The Lancet |
| OLYMPUS | Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101 (Mitomycin Reverse Thermal Gel) | 2020 | 71 | Mitomycin ureteral gel (6 weekly instillations) with optional monthly maintenance | Single-arm | Treatment-naïve or recurrent low-grade noninvasive UTUC (measurable tumor above UPJ) | Complete response at primary disease evaluation | CR rate 59% (95% CI 47%-71%; P<0.0001). Durability at 12 months 84.2% | Median time to recurrence 13 months; most common AEs: ureteric stenosis, UTI, hematuria | Approved for low-grade UTUC; alternative to nephroureterectomy in selected patients | The Lancet Oncology |
| SunRISe-1 (Cohort 2) | TAR-200 (Gemcitabine Intravesical System) for BCG-Unresponsive NMIBC with CIS | 2025 | 85 | TAR-200 (gemcitabine intravesical system) monotherapy | Single-arm | BCG-unresponsive high-risk NMIBC with CIS (with/without Ta/T1) | Complete response rate | CR rate 82.4%; median duration of response 25.8 months; 52.9% with DOR ≥12 months | Grade ≥3 AEs 12.9% (urinary tract pain most common); cystectomy-free survival not reported | TAR-200 approved for BCG-unresponsive NMIBC with CIS; alternative to cystectomy | Journal of Clinical Oncology |
| QUILT-3.032 | N-803 (Nogapendekin Alfa Inbakicept-pmln) Plus BCG for BCG-Unresponsive NMIBC | 2023 | 82 (Cohort A: CIS ± Ta/T1)" | N-803 + BCG | Single-arm | BCG-unresponsive high-risk NMIBC | Complete response rate (Cohort A) and disease-free survival (Cohort B) | Cohort A: CR 71%; median DOR 26.6 months. Cohort B: 12-month DFS 55.4% | Grade ≥3 AEs 2% (combination); favorable quality of life | N-803 + BCG approved for BCG-unresponsive NMIBC with CIS or papillary tumors | NEJM Evidence |
| IMvigor010 ctDNA Analysis | ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (Powles et al. 2025) | 2025 | Not explicitly stated in source; analysis of IMvigor010 trial | Adjuvant atezolizumab | Observation (historical control from IMvigor010) | High-risk MIBC/UTUC post-cystectomy with ctDNA-MRD positivity within 1 year | Not stated in the guideline; trial is referenced as basis for ctDNA-guided therapy | Atezolizumab improved outcomes in ctDNA-MRD positive patients (category 1 per NCCN) | Not provided in guideline | ctDNA-MRD testing recommended to determine adjuvant atezolizumab use (category 1) for patients without prior ICI | New England Journal of Medicine |
Clinical PearlsClick to collapse
- Pearl 1: Immediate post-TURBT intravesical gemcitabine (category 1, preferred) or mitomycin (category 1) reduces 5-year recurrence by ~35% in selected patients with low-grade, low-volume Ta disease; not effective in patients with EORTC recurrence score ≥5 or ≥8 tumors [12-14].
- Pearl 2: For BCG-naïve high-risk NMIBC, BCG induction + maintenance is category 1 for patients without very-high-risk features (lymphovascular invasion, prostatic urethral involvement, variant histology) [130]. For BCG-unresponsive NMIBC, cystectomy or clinical trial is preferred; pembrolizumab is reserved for those who cannot undergo cystectomy [BL-4].
- Pearl 3: Neoadjuvant cisplatin-based chemotherapy (ddMVAC preferred over GC based on VESPER trial) is category 1 for stage II and IIIA MIBC prior to radical cystectomy [183-185]. Carboplatin should not be substituted in the perioperative setting [BL-G 2 of 8].
- Pearl 4: For cisplatin-ineligible patients with MIBC, perioperative enfortumab vedotin + pembrolizumab followed by cystectomy is an option based on KEYNOTE-905 [6].
- Pearl 5: First-line treatment for advanced/metastatic urothelial carcinoma: enfortumab vedotin + pembrolizumab is the preferred category 1 regimen regardless of cisplatin eligibility, based on EV-302 (median OS 31.5 vs 16.1 months, HR 0.47) [260]. Avelumab maintenance is category 1 after first-line platinum-based chemo without progression [282].
- Pearl 6: In the second-line setting (post-platinum and post-checkpoint inhibitor), enfortumab vedotin (category 1) or erdafitinib (category 1 for FGFR3-altered) are preferred options [293,297].
- Pearl 7: Bladder preservation with trimodality therapy (maximal TURBT + concurrent chemoradiotherapy) is category 1 for stage II/IIIA MIBC in appropriate candidates (solitary tumor, no hydronephrosis, no extensive CIS, good bladder function) [BL-6, BL-H 1 of 3].
- Pearl 8: ctDNA-MRD testing using an FDA-approved personalized tumor-informed assay is recommended post-cystectomy for risk stratification and to guide adjuvant atezolizumab (category 1) in patients without prior immunotherapy [43] (BL-I 2 of 3).
- Pearl 9: For UTUC, the POUT trial supports adjuvant platinum-based chemotherapy for pT2-4 or N+ disease after nephroureterectomy [344]. Neoadjuvant chemotherapy should be considered for high-risk UTUC as renal function declines after surgery [BL-G 2 of 8].
- Pearl 10: DPYD testing should be considered before fluoropyrimidine therapy (e.g., capecitabine, 5-FU) to identify patients at risk for severe toxicity [BL-G 6 of 8].